Used in the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is also indicated for moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. The compound works by modulating the sphingosine 1-phosphate receptor, reducing the migration of lymphocytes into the central nervous system and the gastrointestinal tract, thereby decreasing inflammation and autoimmune activity. Its selective action allows for effective immune modulation with a favorable safety profile compared to broader immunosuppressants.